University of Coimbra

The University of Coimbra represented by CIBIT (Coimbra Institute of Biomedical Imaging and Translational Research) and ICNAS (Institute of Nuclear Sciences Applied to Health) are highly involved in multimodal brain imaging with a focus on brain cancer. UDC has facilities for 3T MRI, PET and other imaging modalities that are in routine use in clinical practice in addition to a team of radiologists, neuroradiologists, nuclear medicine physicians and physicists who are the cornerstone of the institution. CIBIT, as a research institute, is mainly concerned with multimodal brain imaging in health and disease. In addition to cancer imaging, we are also interested in cognitive neuroscience, brain mapping and non-invasive brain stimulation with TMS and tDCS.

Role of institution in the project

UDC will be mainly involved in WP2 and 5 to provide use-cases and imaging data of primary brain malignancies. Additionally, UDC will provide a use-case of glioblastoma cases for WP4 for testing purposes. In addition to providing sample data, we will also be involved in clinical testing and validation of the platform. The use-cases will eventually include glioblastoma, astrocytoma and meningioma.

Prof. Miguel Castelo-Branco

Prof Miguel Castelo-Branco (MD PhD) is the Director of CIBIT, the Coimbra Institute for Biomedical Imaging and Translational Research and has been the Director of IBILI, a leading Vision Research Institute in Portugal. He is the Scientific Coordinator of the National Functional Brain Imaging Scientific initiative. He was also the Director of ICNAS, the Medical Imaging Infrastructure at the University of Coimbra. Under his leadership IBILI was classified as an Excellent Research Unit by international evaluation panels. MCB has made interdisciplinary contributions in the fields of Cognitive Neuroscience, Human and Animal Neurophysiology, Visual Neuroscience, Human Psychophysics, Functional Brain Imaging and translational research in Neurology. His lab has accomplishing tasks in the context of several European Networks, (Evi-Genoret, BACS, e-Rare Consortia, BrainTrain, Stiped), and has succeed in collaborating with labs working in other fields of knowledge such as Human Genetics and Clinical Neuroscience.

Sulaiman I.S. Abuhaiba

Sulaiman I.S. Abuhaiba (MD PhD) has a doctorate in brain imaging and neuroelectrophysiology. SA has solid experience of more than 10 years and skills in working with EEG, MRI, fMRI, MEG, MRS, and PET. His work ranges from basic cognitive neuroscience to advanced analysis for diagnostic purposes in patients with medically refractory epilepsy secondary to brain tumors. He is also involved in public health awareness programs related to Epilepsy.

João Castelhano

João Castelhano (JC) has a Master in Biomedical Engineering and completed the Ph.D. degree in health sciences (biomedical sciences) in 2015 by the Faculty of Medicine, University of Coimbra (UC). JC is a Researcher in the field of medical imaging and radiation working particularly in Multimodal Imaging and signal Processing. His main research activities included neuroscience, multimodal medical imaging translational research and new imaging biomarkers and data analysis developments including Big Data approaches. JC is an important team member of research projects that extend from the pre-clinical to the clinical studies.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.